



European Investment Bank (EIB)

Luxembourg, 17 December 2018

Environmental and Social Completion Sheet (ESCS)

Overview

Project Name:	Ferrer Pharmaceutical RDI II
Project Number:	2014-0192
Country:	Spain
Project Description:	The project covers the Promoter's research activities in the fields of infections and inflammatory diseases, oncology, diagnostics, and development in cardiovascular, respiratory and other therapeutic areas such as the central nervous system.

Summary of Environmental and Social Assessment at Completion

EIB notes the following key Environmental and Social outcomes at Project Completion.

No significant environment or social issues were noted. The project concerned investments in research and development activities carried out in existing facilities already authorised for that purpose. The use of any animals for scientific research purposes within the scope of the project, if applicable, has been conducted in compliance with directive 2010/63/EU.

Overall, the project has been assessed as acceptable, having no adverse impact on the environment. The RDI activities undertaken in the project are aiming to result in new and improved treatments for diseases in different therapeutic areas, thus potentially generating a positive social impact.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion, based on reports from the promoter, that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.